Drug intelligence / Profile preview

C-FI-01

Development stage: Preclinical
Lead developer: Curatis
Modality: Small Molecules

Overview

C-FI-01 is an investigational drug candidate currently in the preclinical stage of development by Curatis Group. It is being developed for the treatment of fibrotic or inflammatory orphan and ultra-orphan diseases. As of the current pipeline disclosures, the specific molecular target, mechanism of action, and modality of the compound remain proprietary and have not been publicly released. The asset represents the earliest stage of the company's clinical development pipeline, targeting rare conditions with high unmet medical needs.

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on C-FI-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-FI-01.

Explore the full profile